NovoCure (NVCR) Revenue (2014 - 2026)

NovoCure has disclosed Revenue across 13 years of filings, most recently posting $183.6 million for Q2 2026.

• In Q2 2026, Revenue rose 15.6% year-over-year to $183.6 million; the TTM figure through Jun 2026 stood at $699.2 million (up 10.95% YoY), while the FY2025 annual figure was $655.4 million, up 8.28% from the prior year.
• Revenue came in at $183.6 million for Q2 2026 at NovoCure, up from $174.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $183.6 million in Q2 2026 to a low of $122.2 million in Q1 2023.
• Average Revenue over 5 years is $148.1 million, with a median of $145.6 million recorded in 2022.
• Year-over-year, Revenue retreated 11.17% in 2023 and advanced 21.81% in 2024.
• Over 5 years, Revenue stood at $128.4 million in 2022, then advanced by 4.17% to $133.8 million in 2023, then rose by 20.54% to $161.3 million in 2024, then grew by 8.11% to $174.4 million in 2025, then rose by 5.3% to $183.6 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $183.6 million in Q2 2026, $174.1 million in Q1 2026, and $174.4 million in Q4 2025.